Edwards Lifesciences officer plans 50K share sale

Edwards Lifesciences Corp. received a Form 144 notice relating to a proposed sale of up to 50,000 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value of $4,625,000.00, expected on or about 07/30/2026 on the NYSE.

Rhea-AI Filing Summary

Edwards Lifesciences Corp. received a Form 144 notice relating to a proposed sale of up to 50,000 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value of $4,625,000.00, expected on or about 07/30/2026 on the NYSE.

The shares are tied to equity compensation awards designated as RSU / PSU dated 02/20/2018. During the past three months, a separate transaction reported the sale of 64,152 shares for $5,555,061.00 on 05/29/2026. Shares outstanding were 575,800,000, a baseline figure, not the amount being offered.

Key Figures

Proposed shares to be sold: 50,000 shares Aggregate market value of proposed sale: $4,625,000.00 Shares outstanding baseline: 575,800,000 shares +3 more

6 metrics

Proposed shares to be sold 50,000 shares Common stock under Form 144 notice via Charles Schwab & Co., Inc.

Aggregate market value of proposed sale $4,625,000.00 Value of 50,000 shares of common stock expected to be sold 07/30/2026

Shares outstanding baseline 575,800,000 shares Context figure for Edwards Lifesciences common stock shares outstanding

Shares sold in past 3 months 64,152 shares Sale on 05/29/2026 disclosed as prior three-month transaction

Value of past 3-month sale $5,555,061.00 Total proceeds from 64,152-share sale on 05/29/2026

Equity award reference date 02/20/2018 Date tied to RSU / PSU equity compensation for 50,000 shares

Key Terms

Form 144, RSU, PSU, equity compensation

4 terms

Form 144 regulatory

"Edwards Lifesciences Corp. received a Form 144 notice relating to a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU financial

"The shares are tied to equity compensation awards designated as RSU / PSU dated 02/20/2018"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

PSU financial

"The shares are tied to equity compensation awards designated as RSU / PSU dated 02/20/2018"

A PSU is a company where the government owns a controlling stake and often plays a direct role in its management and strategy. Think of it like a business that operates with public oversight, similar to a town-run utility versus a private neighborhood service. Investors watch PSUs differently because government involvement can affect profits, dividend policies, regulatory treatment and stability, so these stocks may behave more like policy instruments than pure market-driven enterprises.

equity compensation financial

"The shares are tied to equity compensation awards designated as RSU / PSU"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Edwards Lifesciences (EW) disclose in this Form 144 filing?

The filing reports a proposed sale of up to 50,000 shares of Edwards Lifesciences common stock, with an aggregate market value of $4,625,000.00, to be sold on or about 07/30/2026 through Charles Schwab & Co., Inc. on the NYSE.

Who is the reporting person in the Edwards Lifesciences (EW) Form 144?

The reporting person is Scott B. Ullem, with an address at One Edwards Way, Irvine, CA 92614. The notice covers a proposed sale of 50,000 shares of Edwards Lifesciences common stock related to previously granted equity compensation awards.

How many Edwards Lifesciences (EW) shares are proposed to be sold and at what value?

The notice covers up to 50,000 shares of Edwards Lifesciences common stock, with an aggregate market value listed as $4,625,000.00. These shares are expected to be sold on or about 07/30/2026 on the NYSE through Charles Schwab & Co., Inc.

What prior sales are disclosed for Edwards Lifesciences (EW) in the last three months?

The Form 144 references a prior sale of 64,152 shares of Edwards Lifesciences common stock on 05/29/2026 for total proceeds of $5,555,061.00. This entry appears under securities sold during the past three months, separate from the newly proposed 50,000-share sale.

How were the Edwards Lifesciences (EW) shares in the Form 144 originally acquired?

The shares are associated with equity compensation awards labeled “RSU / PSU – See Remarks” with a grant or reference date of 02/20/2018. The Form 144 characterizes the source of the stock as equity compensation rather than open-market purchases.

What share count context does the Edwards Lifesciences (EW) Form 144 provide?

The filing lists 575,800,000 shares of Edwards Lifesciences common stock as a context figure for shares outstanding. This represents an overall share baseline and is not the number of shares proposed for sale, which is limited to 50,000 shares in this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:20 PM Accepted by SEC EDGAR 07/30/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001446989
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Ullem Scott B.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	50000	4625000.00	575800000	07/30/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/20/2018	RSU / PSU - See Remarks	EDWARDS LIFESCIENCES CORPORATION			50000	02/20/2018	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SCOTT B ULLEM ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	05/29/2026	64152	5555061.00

144: Remarks and Signature

Remarks	The shares reported on this filing may be sold over various dates in the ULLEM LIVING TRUST and were acquired and paid for between 02/20/2018 and 05/11/2026.
Date of Notice	07/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	SCOTT B ULLEM TTEE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)